Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Lisaftoclax

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China
    Ascentage Pharma’s Lisaftoclax NDA Accepted for Review in China

    17 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-lisaftoclax-accepted-and-recommended-priority-review-designation-by-cde-of-china-nmpa-302307744.html

    PR NEWSWIRE
    17 Nov 2024
    Share Share
    ASH 2024: Ascentage Pharma's Lisaftoclax Data to Be Presented
    ASH 2024: Ascentage Pharma's Lisaftoclax Data to Be Presented

    06 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ash-2024--results-from-three-clinical-studies-of-ascentage-pharmas-bcl-2-inhibitor-lisaftoclax-selected-for-presentations-including-an-oral-report-302297323.html

    PR NEWSWIRE
    06 Nov 2024
    Share Share
    Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis
    Ascentage Releases Lisaftoclax Data At EHA Showing Improvement In Amyloidosis

    18 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-eha-2024--ascentage-pharma-releases-updated-data-of-lisaftoclax-in-patients-with-rr-mm-and-al-amyloidosis-highlighting-marked-improvement-in-orr-302175033.html

    PR NEWSWIRE
    18 Jun 2024
    Share Share
    Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom's Cancer
    Ascentage Pharma: Lisaftoclax Safety/Efficacy Data In Waldenstrom's Cancer

    04 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-asco-2024--ascentage-pharma-releases-updated-data-showing-promising-efficacy-and-safety-of-lisaftoclax-in-patients-with-wm-302164161.html

    PR NEWSWIRE
    04 Jun 2024
    Share Share
    Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax
    Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-presents-the-first-dataset-of-bcl-2-inhibitor-lisaftoclax-in-patients-with-aml-demonstrating-favorable-efficacy-and-safety-302011941.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share
    Ascentage Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax
    Ascentage Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax

    11 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2023--ascentage-pharma-releases-encouraging-long-term-data-of-bcl-2-inhibitor-lisaftoclax-in-rr-cll-including-an-orr-of-73-3-302010995.html

    PR NEWSWIRE
    11 Dec 2023
    Share Share